Advanced hemostasis in trauma, surgery, and endoscopy
CoMotion is an early stage biotechnology startup headquartered in Vancouver, BC and Cambridge, MA.
CoMotion is seeking seed investment, material suppliers, and manufacturing and development partners.
4,000,000+
Hemorrhage deaths per year
3
Bleeding markets targeted
$10,800,000+
Non-dilutive funding
-
Bleeding is a leading cause of preventable death and kills 4M annually. Even when nonlethal, bleeding substantially increases disability and care burden. CoMotion is developing a pipeline of next-generation advanced hemostatic drug-device products to address traumatic, surgical, and gastrointestinal (GI) hemorrhage. Our mission is to reduce death and disability following trauma and to improve in-hospital hemorrhage control using our proprietary drug delivery platform - CounterFlow™.
-
CoMotion is developing a hemostatic drug-delivery platform, CounterFlow™, capable of deployment via various applicator formats to address muitiple types of bleeds. CounterFlow™ is a mixture of calcium carbonate combined with tranexamic acid (TXA) and thrombin, which are each FDA-approved for hemostasis. Upon contact with blood, the carbonate and tranexamic acid effervescently react, to disperse the hemostatic agents into the bleed to rapidly achieve primary hemostasis and stabilize patients.
CoMotion’s cofounders have published many peer-reviewed scientific articles showing that CounterFlow™ stops bleeding in multiple models of severe hemorrhage. See “Papers and news” for more.
-
CounterFlow™ has been developed in partnership with multiple government and academic instutions:
US Department of Defense
Canadian Department of National Defence
University of British Columbia (Vancouver, BC)
Medical College of Wisconsin (Milwaukee, WI)
Versiti Blood Research Institute (Milwaukee, WI)
CoMotion’s Founders
James received his PhD in Biomedical Engineering in 2018 from the University of British Columbia where his thesis was on the invention and proof-of-concept of the CounterFlow platform. He did his postdoctoral studies at Harvard Medical School researching biomaterials for drug delivery. James advanced his expertise as a Senior Scientist at Novo Nordisk in Drug Product Research.
Christian is a Professor of Surgery at Medical College of Wisconsin, Senior Investigator and Program Co-leader at Versiti Blood Research Institute and Affiliate Professor at University of British Columbia. Christian brings deep expertise in trauma, surgery, and hemostasis with 15 years inventing and translating new hemostatic technologies. Christian has founded multiple other biotechnology startups, including SeraGene Therapeutics and NanoVation Therapeutics.